RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsJuly 29, 2024 - Big Pharma company Boehringer Ingelheim is acquiring preclinical small molecule checkpoint inhibitor company Nerio Therapeutics Inc. (“Nerio”) for USD 1.3 billion.
Nerio has been working on small molecules that inhibit protein tyrosine phosphatases N1 and N2 that have shown potential to “reshape the immune landscape of the tumor microenvironment,” the La Jolla, California-based biotech claims.
https://www.fiercebiotech.com/biotech/boehringer-pays-13b-acquire-nerio-and-its-preclinical-checkpoint-inhibitors